Which hedge funds own RGEN? REPLIGEN CORP, Q2 2026 13F holders
Healthcare · Open on the interactive board
14 of the hedge funds tracked by WhaleCreep disclosed a position in RGEN (REPLIGEN CORP) in their Q2 2026 13F filings, worth $602.6m in total. The largest holder by portfolio weight is Maverick Capital at 2.4% of its book. 7 managers opened a new position this quarter: Duquesne Family Office LLC, Moore Capital Management, Marshall Wace, Tudor Investment. 1 exited: Point72 Asset Management LP.
14tracked managers holding
7opened this quarter
1exited this quarter
Which hedge funds hold RGEN? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Maverick Capital | Q2 2026 | 2.4% | $270.8m | 1,984,554 | 31% | added |
| Avidity Partners | Q2 2026 | 1.7% | $10.6m | 77,800 | 0% | held |
| Holocene Advisors | Q2 2026 | 0.4% | $176.3m | 1,292,191 | 82% | added |
| Duquesne Family Office LLC | Q2 2026 | 0.2% | $10.6m | 77,400 | – | new |
| Moore Capital Management | Q2 2026 | 0.1% | $5.1m | 37,549 | – | new |
| Point72 Asset Management LP | Q2 2026 | 0.0% | $22.7m | 166,157 | -71% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $38.5m | 282,107 | – | new |
| Citadel Advisors | Q2 2026 | 0.0% | $51.3m | 376,309 | -66% | reduced |
| Tudor Investment | Q2 2026 | 0.0% | $3.5m | 25,678 | – | new |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $11.4m | 83,328 | – | new |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $202.1k | 1,481 | – | new |
| First Manhattan | Q2 2026 | 0.0% | $732.0k | 5,365 | -18% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $928.6k | 906,000 | – | new |
| Ancora Advisors | Q2 2026 | 0.0% | $1.6k | 12 | 0% | held |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Point72 Asset Management LP | 0.1% | $4.9m |
How has hedge fund ownership of RGEN changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 14 | $602.6m |
| Q1 2026 | 8 | $476.5m |
| Q4 2025 | 10 | $383.2m |
| Q3 2025 | 11 | $459.0m |
| Q2 2025 | 11 | $554.1m |
| Q1 2025 | 7 | $454.5m |
| Q4 2024 | 6 | $394.1m |
| Q3 2024 | 5 | $280.2m |
| Q2 2024 | 7 | $241.7m |
| Q1 2024 | 5 | $443.8m |
| Q4 2023 | 6 | $481.7m |
| Q3 2023 | 5 | $275.6m |
| Q2 2023 | 4 | $244.5m |
| Q1 2023 | 3 | $294.2m |
| Q4 2022 | 5 | $589.5m |
| Q3 2022 | 6 | $659.6m |
Counts every tracked manager that disclosed RGEN in that quarter's filing, including managers that have since stopped filing.